Clinical Trials Sponsored by Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Total 63 results

ViMREX GmbH
Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus...

Active, not recruiting

Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN) (DelVIN)

Vulvar Intraepithelial Neoplasia Grade 2 | Vulvar Intraepithelial Neoplasia Grade 3

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

The PLATON Network (PLATON)

Stomach Cancer | Pancreatic Cancer | Cholangiocarcinoma | Gallbladder Cancer | Hepatocellular Cancer | Oesophageal Cancer

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION)- a Permanent Platform Including All Kind of Biliary Tract Cancers (BTC)

Biliary Tract Cancer | Neoadjuvant, Adjuvant and 1st Line

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Hepatocellular Carcinoma

Austria, Germany, Spain, Japan, Italy, France
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma

Esophagogastric Adenocarcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Completed

Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction (RE-ExPEL)

Gastric Adenocarcinoma | Metastatic Adenocarcinoma of the Gastroesophageal Junction

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Completed

Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer

Gastric Cancer

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Solid Tumors | Peritoneal Carcinomatosis

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

NSCLC

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

GastroEsophageal Cancer | Adenocarcinoma of the Stomach

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Terminated

Trial Comparing Parenteral Nutrition (PN) Using Eurotubes® vs. 2/3-chamber Bags in Subjects With Solid Tumors Requiring PN (PEKANNUSS) (PEKANNUSS)

Solid Tumor

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Terminated

CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study

Advanced Renal Cell Carcinoma (All Subtypes) | Metastatic Renal Cell Carcinoma (All Subtypes)

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Completed

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) (RAMSES/FLOT7)

Stomach Cancer | Gastroesophageal Junction Cancer

Germany, Italy
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery

Esophagus Adenocarcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Intrahepatic Cholangiocarcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

GISAR German Interdisciplinary Sarcoma Registry (GISAR)

Sarcoma | Carcinosarcoma | Sarcoma,Soft Tissue | Sarcoma of Bone

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Recruiting

Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (RAMIRIS)

Advanced Gastric or EGJ Cancer

Germany, Austria, Italy
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder Carcinoma"

Gallbladder Carcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Intrahepatic Cholangiocarcinoma | Hilar Cholangiocarcinoma | Distal Cholangiocarcinoma | Gall Bladder Carcinoma | Biliary Tract Cancer (CCA)

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Active, not recruiting

IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC)

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Completed

Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.

Metastatic Colorectal Cancer

Germany
Institut für Klinische Krebsforschung IKF GmbH...

Terminated

OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

Advanced Soft Tissue Sarcoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Thoraxklinik-Heidelberg gGmbH

Active, not recruiting

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease (TREASURE)

Thoracic Radiotherapy | Small Cell Lung Cancer Extensive Stage

Germany, Austria
North Eastern German Society of Gynaecological...
PharmaMar; Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Completed

Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer (COMPASS)

Quality of Life | Ovarian Cancer | Recurrent Ovarian Carcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Ipsen

Recruiting

Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment

Hepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular Carcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
PharmaMar

Recruiting

Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients (PROTraSarc)

Soft Tissue Sarcoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca

Recruiting

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Intrahepatic Cholangiocarcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Celgene

Completed

PARAGON Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer (PARAGON)

Pancreatic Adenocarcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Thoraxklinik-Heidelberg gGmbH

Recruiting

Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (TRADE-hypo)

NSCLC, Stage III

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Gilead Sciences

Recruiting

Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

Germany, Austria
Institut für Klinische Krebsforschung IKF GmbH...
Trium Analysis Online GmbH

Completed

FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer (PETRARCA)

Stomach Cancer | Gastroesophageal Junction Cancer

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG

Recruiting

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness (DANTE)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Germany, Switzerland
University Hospital Heidelberg
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest

Completed

Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC (PICCASSO)

Metastatic Colorectal Cancer | MSS

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Bristol-Myers Squibb; Eisai GmbH

Completed

Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
EUSA Pharma, Inc.

Recruiting

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc)

Leiomyosarcoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG

Recruiting

PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) (PLATON)

Stomach Cancer | Pancreatic Cancer | Cholangiocarcinoma | Gallbladder Cancer | Hepatocellular Cancer | Oesophageal Cancer

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Pleural Mesothelioma Malignant

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG; Thoraxklinik-Heidelberg gGmbH

Recruiting

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Non-small Cell Lung Cancer

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Incyte Biosciences International Sàrl

Recruiting

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Gene Translocation | FGFR2 Gene Rearrangement

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Hannover Medical School; AstraZeneca

Recruiting

Durvalumab and Tremelimumab in Combination With Either Y-90 SIRT or DEB-TACE for Intermediate Stage HCC

HCC | Hepatocellular Carcinoma Non-resectable

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Trium Analysis Online GmbH; mca Berlin

Completed

Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program (QoliXane)

Metastatic Pancreatic Cancer

Germany
AIO-Studien-gGmbH
Sanofi; Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt

Completed

mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer

Rectal Cancer | Rectosigmoid Cancer

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Merck Sharp & Dohme LLC; Organon Healthcare GmbH

Active, not recruiting

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Eli Lilly and Company; Trium Analysis Online GmbH

Completed

Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy (RAMOS)

Squamous Cell Carcinoma of the Esophagus

Germany
Institut für Klinische Krebsforschung IKF GmbH...
Eli Lilly and Company; Trium Analysis Online GmbH

Active, not recruiting

RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS)

Colorectal Cancer

Germany
Universitätsmedizin Mannheim
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Deutsche...

Active, not recruiting

Neoadjuvant RCT Versus CT for Patients With Locally Advanced, Potentially Resectable Adenocarcinoma of the GEJ

Gastroesophageal Junction Adenocarcinoma

Germany
Institut für Klinische Krebsforschung IKF GmbH...
AstraZeneca; Universitätsklinikum Köln, Germany; Universitätsklinikum Düsseldorf...

Not yet recruiting

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

Extrahepatic Cholangiocarcinoma | Unresectable Perihilar or Ductal CCA

Germany
North Eastern German Society of Gynaecological...
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Not yet recruiting

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy (N-Plus)

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Clear Cell Carcinoma
University Medicine Greifswald
Bristol-Myers Squibb; Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus... and other collaborators

Completed

Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas (NiTraSarc)

Metastatic Adult Soft Tissue Sarcoma

Germany

Clinical Trials Sponsored by Frankfurter Institut für Klinische Krebsforschung IKF GmbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations